-
1 Comment
Aier Eye Hospital Group Co., Ltd is currently in a long term uptrend where the price is trading 18.2% above its 200 day moving average.
From a valuation standpoint, the stock is 151.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 24.2.
Aier Eye Hospital Group Co., Ltd's total revenue rose by 47.6% to $4B since the same quarter in the previous year.
Its net income has increased by 62.3% to $870M since the same quarter in the previous year.
Finally, its free cash flow grew by 157.0% to $2B since the same quarter in the previous year.
Based on the above factors, Aier Eye Hospital Group Co., Ltd gets an overall score of 4/5.
| Industry | Medical Care Facilities |
|---|---|
| Sector | Healthcare |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100000GR6 |
| Market Cap | 118B |
|---|---|
| PE Ratio | 32.15 |
| Beta | 0.84 |
| Target Price | 14.5392 |
| Dividend Yield | 1.2% |
Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. The company operates ophthalmic hospitals in mainland China, Europe, the United States, Hong Kong, and Southeast Asia. The company was founded in 2007 and is headquartered in Changsha, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300015.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
